GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Additional Paid-In Capital

MaxCyte (LSE:MXCT) Additional Paid-In Capital : £323.17 Mil(As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is MaxCyte Additional Paid-In Capital?


MaxCyte's quarterly additional paid-in capital declined from Sep. 2023 (£325.51 Mil) to Dec. 2023 (£321.47 Mil) but then increased from Dec. 2023 (£321.47 Mil) to Mar. 2024 (£323.17 Mil).

MaxCyte's annual additional paid-in capital increased from Dec. 2021 (£282.90 Mil) to Dec. 2022 (£320.86 Mil) and increased from Dec. 2022 (£320.86 Mil) to Dec. 2023 (£321.47 Mil).

MaxCyte Additional Paid-In Capital Historical Data

The historical data trend for MaxCyte's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Additional Paid-In Capital Chart

MaxCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 73.58 94.99 282.90 320.86 321.47

MaxCyte Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 325.93 316.18 325.51 321.47 323.17

MaxCyte Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

MaxCyte Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of MaxCyte's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte (LSE:MXCT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (LSE:MXCT) » Definitions » Additional Paid-In Capital
Comparable Companies
LSE:NIOX LSE:EKF LSE:CREO LSE:BELL LSE:IUG LSE:IHC LSE:POLX LSE:SUN LSE:MHC LSE:DEMG ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
MXCT:USA MYE0:Germany
Address
9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850
Website
https://www.maxcyte.com
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.